MK-1775, a novel wee1 kinase inhibitor,radiosensitizes p53-defective human tumor cells

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5638-5648

  Bridges, Kathleen A ^a   Hirai, Hiroshi ^b   Buser, Carolyn A ^c   Brooks, Colin ^a   Liu, Huifeng ^a   Buchholz, Thomas A ^a   Molkentine, Jessica M ^a   Mason, Kathryn A ^a   Meyn, Raymond E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H2AX; MK 1775; PROTEIN P53; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; WEE1 KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MITOSIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIZATION; TUMOR CELL; TUMOR GROWTH; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASMS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052491760     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0650     Document Type: Article

References (29)

1. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331 (Pubitemid 27131374)
2. Vousden K.H., Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002;2:594-604. (Pubitemid 37328926)
3. Su T.T. Cellular responses to DNA damage: One signal, multiple choices. Annu Rev Genet 2006;40:187-208. (Pubitemid 44956784)
4. Elledge S.J. Cell cycle checkpoints: Preventing an identity crisis. Science 1996;274:1664-1672 (Pubitemid 26414889)
5. Eriksson D., Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol 2010;31:363-372
6. Yao S.L., Akhtar A.J., McKenna K.A., Bedi G.C., Sidransky D., Mabry M., et al. Selective radiosensitization of p53-deficient cells bycaffeine-mediated activation of p34cdc2 kinase. Nat Med 1996;2: 1140-1143 (Pubitemid 26338635)
7. Wang Q., Fan S., Eastman A., Worland P.J., Sausville E.A., O'Connor P.M. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-965 (Pubitemid 26239383)
8. Powell S.N., DeFrank J.S., Connell P., Eogan M., Preffer F., Dombkowski D., et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 1995;55:1643-1648
9. Leijen S., Beijnen J.H., Schellens J.H. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 2010;5: 186-191
10. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-519
11. Iliakis G., Wang Y., Guan J., Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003;22:5834-5847 (Pubitemid 37176704)
12. Huang H., Fletcher L., Beeharry N., Daniel R., Kao G., Yen T.J., et al. Abnormal cytokinesis after X-irradiation in tumor cells that override the G2 DNA damage checkpoint. Cancer Res 2008;68:3724-3732
13. Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990;344:503-508
14. Nurse P. Checkpoint pathways come of age. Cell 1997;91:865-867 (Pubitemid 28027819)
15. O'Connell M.J., Raleigh J.M., Verkade H.M., Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997;16:545-554 (Pubitemid 27067784)
16. Zhou B.B., Elledge S.J. The DNA damage response: Putting check-points in perspective. Nature 2000;408:433-439
17. Wang Y., Decker S.J., Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004;3:305-313 (Pubitemid 41350885)
18. Wang Y., Li J., Booher R.N., Kraker A., Lawrence T., Leopold W.R., et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001;61:8211-8217 (Pubitemid 33091614)
19. Hirai H., Iwasawa Y., Okada M., Arai T., Nishibata T., Kobayashi M., et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009;8:2992-3000.
20. Mueller P.R., Coleman T.R., Kumagai A., Dunphy W.G. Myt1: A membrane- associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995;270:86-90.
21. Hirai H., Arai T., Okada M., Nishibata T., Kobayashi M., Sakai N., et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-522
22. Schellens J.H., Leijen S., Shapiro G.I., Pavlick A.C., Tibes R., O'Day S.J., et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors [abstract]. In: Proceedings of the 46th Annual Meeting of the American Society of Clinical Oncology; 2010; Chicago, IL: ASCO; 2010. p. 28. Abstract nr 3510.
23. Nakamura S., Roth J.A., Mukhopadhyay T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 2000;20:9391-9398 (Pubitemid 32246123)
24. Sah N.K., Munshi A., Nishikawa T., Mukhopadhyay T., Roth J.A., Meyn R.E. Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity. Mol Cancer Ther 2003;2:1223-1231
25. Mir S.E., De Witt Hamer P.C., Krawczyk P.M., Balaj L., Claes A., Niers J.M., et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010;18:244-257
26. Indovina P., Giordano A. Targeting the checkpoint kinase WEE1: Selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther 2010;9:523-525
27. Stathis A., Oza A. Targeting Wee1-like protein kinase to treat cancer. Drug News Perspect 2010;23:425-429
28. Stark G.R., Taylor W.R. Control of the G2/M transition. Molecular biotechnology 2006;32:227-248
29. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803-1815 (Pubitemid 32458690)